Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.66 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | DRD4 | P21917 | 11/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15550981 | 0.89 | HTT (0.61) | GRIN1GRIN2BHTTDRD4HPGD | |
| SCHEMBL5157052 | 0.82 | HTT (0.84) | GRIN1GRIN2BHTTDRD4HPGD | |
| SCHEMBL16795300 | 0.82 | DRD4 (0.67) | GRIN1GRIN2BHTTDRD4HPGD | |
| SCHEMBL4791717 | 0.82 | CHRNA7 (0.77) | GRIN1GRIN2BHTTDRD4HPGD | |
| SCHEMBL6941438 | 0.81 | HTT (0.69) | GRIN1GRIN2BHTTDRD4HPGD | |
| SCHEMBL7085421 | 0.80 | IDO1 (0.67) | GRIN1GRIN2BNPC1GAAKDM4E | |
| SCHEMBL14338810 | 0.80 | HPGD (0.55) | GRIN1GRIN2BHTTDRD4HPGD | |
| SCHEMBL7085424 | 0.80 | IDO1 (0.67) | GRIN1GRIN2BNPC1GAAKDM4E | |
| SCHEMBL7086561 | 0.80 | IDO1 (0.67) | GRIN1GRIN2BNPC1GAAKDM4E | |
| SCHEMBL1388535 | 0.80 | GRIN2B (1.00) | GRIN1GRIN2BHTTDRD4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | VIM, MATR3, TP53 | GRIN1 4074/4885GRIN2B 4318/4885HTT 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.